Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™

P., T.; Wade, Sally; Anthony, Mary S.; Downs, Robert W.

doi:10.1007/s00198-009-1133-5

Cited by 29 publications

(24 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We therefore believe that side effects, and in particular, gastrointestinal tolerability may be an important contributing factor related to treatment persistence [33][34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results

et al. 2010

View full text Add to dashboard Cite

Summary-Persistence with osteoporosis therapy remains low and identification of factors associated with better persistence is essential in preventing osteoporosis and fractures. In this study, patient understanding of dual energy X-ray absorptiometry (DXA) results and beliefs in effects of treatment were associated with treatment initiation and persistence.Introduction-The purpose of this study is to examine patient understanding of their DXA results and evaluate factors associated with initiation of and persistence with prescribed medication in first-time users of anti-osteoporotic agents. Self-reported DXA results reflect patient understanding of diagnosis and may influence acceptance of osteoporosis therapy. To improve patient understanding of DXA results, we provided written information to patients and their referring general practitioner (GP), and evaluated factors associated with osteoporosis treatment initiation and 1-year persistence.

show abstract

“…We therefore believe that side effects, and in particular, gastrointestinal tolerability may be an important contributing factor related to treatment persistence [33][34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Costeffectiveness studies based on clinical trial information have shown that treatment of osteoporosis is a cost-effective intervention for the patients with a risk of fracture defined in clinical trials and guidelines for intervention [8,53]. However, the adherence to therapy in clinical practice, both patient-reported and register-based, is much lower than in clinical trials [20,54]. This does not invariably change the cost-effectiveness of the intervention when compared with no treatment, since patients who drop out of treatment lose both costs and effects.…”

Section: Persistencementioning

confidence: 99%

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

et al. 2010

View full text Add to dashboard Cite

Summary-Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate the cost-effectiveness of denosumab in a Swedish setting, also accounting for poor adherence to treatment. Denosumab is cost-effective, particularly for patients at high risk of fracture and low adherence to oral treatments.Introduction-Denosumab is a novel biologic agent developed for the treatment of osteoporosis and osteoporotic fractures that has been shown to reduce the risk of fractures in a phase III trial. The objective of this study was to estimate the cost-effectiveness of denosumab from a societal perspective compared with generic alendronate, branded risedronate, strontium ranelate, and no treatment in a Swedish setting.

show abstract

“…Each participant was classified into one of five mutually exclusive treatment status cohorts using physician-reported medication history provided at study entry: new to therapy, stable on therapy, having recently switched therapy, having recently augmented therapy, or using calcium and/or vitamin D alone [21,22].…”

Section: Data Source and Study Populationmentioning

confidence: 99%

Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™

Barrett‐Connor

Wade

et al. 2011

Osteoporos Int

Self Cite

View full text Add to dashboard Cite

show abstract

Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™

Abstract: Baseline osteoporosis medication transitions were common in the first year of POSSIBLE US. Participants not on stable therapy at entry, or who reported severe side effects, or had poor physical health status were at higher risk for these transitions.

Cited by 29 publications

References 18 publications

Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results

Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™

Contact Info

Product

Resources

About